Keyword: Dana-Farber Cancer Institute
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
The Harvard researcher who first discovered the "exercise hormone" irisin reports it may be useful in bone formation.
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Eli Lilly doubles down on its collaboration with the Dana-Farber Cancer Institute, extending the partnership for another three years.
Chief Scientific Officer Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner.
The thoracic oncologist will head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results in mouse models.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
